

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/96347/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Morris, Ceri A., El-Hiti, Gamal A., Weeks, Ian , Woodhead, Stuart, Smith, Keith and Kille, Peter 2017. Quantitative analysis of gene expression changes in response to genotoxic compounds. *Toxicology in Vitro* 39 , pp. 15-28. 10.1016/j.tiv.2016.11.004

Publishers page: <http://dx.doi.org/10.1016/j.tiv.2016.11.004>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Quantitative analysis of gene expression changes in response to genotoxic compounds.

Ceri A. Morris^{a,b,*}, Gamal A. El-Hiti^c, Ian Weeks^b, Stuart Woodhead^d, Keith Smith^e, Peter Kille^a

^a School of Biosciences, Cardiff University, Cardiff CF10 3AT, UK

^b School of Medicine, Cardiff University, Tenovus Building, Heath Park, Cardiff CF14 4XN, UK

^c Cornea Research Chair, Department of Optometry, College of Applied Medical Sciences, King Saud University, P.O. BOX 10219, Riyadh 11433, Saudi Arabia

^d Invitron, Wyastone Leys, Monmouth NP25 3SR, UK

^e School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK

* Corresponding author at: School of Medicine, Cardiff University, Tenovus, Heath Park, Cardiff CF14 4XN, UK.

E-mail address: morrisc10@cardiff.ac.uk; Tel. +44 (0)2920 874507 (C. A. Morris).

ABSTRACT

Techniques that quantify molecular endpoints sufficiently sensitive to identify and classify potentially toxic compounds have wide potential for high-throughput *in vitro* screening. Expression of three genes, *RAD51C*, *TP53* and cystatin A (*CSTA*), in HEPG2 cells was measured by Q-PCR amplification. In parallel, we developed alternative assays for the same 3 gene signature based on an acridinium-ester chemiluminescent reporter molecule.

HEPG2 cells were challenged with eighteen different compounds (n=18) chosen to represent compounds that are genotoxic (n=8), non-genotoxic non-carcinogenic (n=2) or have a less well defined mechanism of action with respect to genotoxicity (n=8). At least one of the three genes displayed dysregulated expression in the majority of compounds tested by Q-PCR and ten compounds changed the *CSTA* expression significantly.

Acridinium-ester labelled probes for the three genes were synthesised and tested. Analytical sensitivity was characterised and suggested a limit of detection generally better than 0.1 fmol but often 10-50 attomol. A linear amplification step was optimised and this quantitative method detected statistically significant increases in *RAD51C* and *CSTA* expression in agreement with the Q-PCR results, demonstrating the potential of this technology. The broad agreement of the amplified chemiluminescent method and Q-PCR in measuring gene expression suggests wider potential application for this chemiluminescent technology.

Keywords: acridinium-ester, chemiluminescence, genotoxic, cystatin A (CSTA), RAD51C, tumour suppressor p53 (TP53)

1. Introduction

Assays based on the use of acridinium-ester (AE) as a chemiluminescent reporter molecule are well described in the literature (Arnold *et al.*, 1989; Nelson *et al.*, 1996 a,b) and are applied to the measurement of highly abundant ribosomal RNA of infectious agents. However, this technology has wider application as it is capable of measuring less abundant messenger RNA transcripts in a sensitive and quantitative fashion (Thomas *et al.*, 2003a,b) with exquisite specificity (Morris *et al.*, 2014). Here we aimed to extend the technology further by developing more sensitive chemiluminescent methods capable of measuring gene expression changes for toxicological application in conjunction with *in vitro* models.

To this end, the human hepatoma HEPG2 cell line was chosen as the test system. Although no cell model can perfectly mimic the *in vivo* situation, HEPG2 cells are often used in *in vitro* studies of toxicity as they express many of the phase I and II detoxification enzymes and a functioning gene (*TP53*) associated with the TP53 protein (Westerink and Schoonen, 2007a,b). Three genes were identified as potential targets of interest: *RAD51C*, *TP53* and cystatin A (*CSTA*) primarily based on a publication by Westerink *et al.*, (2010) which identified these genes from microarray analysis and demonstrated their potential with genotoxic compounds in HEPG2 cells in the form of reporter gene assays. The RAD family including *RAD51C* was also found to have altered gene expression in response to metal carcinogenesis (Kawata *et al.*, (2009). Using genotoxic compounds identified from the publication by Kirkland *et al.* (2008), the gene expression in response to eighteen compounds with different mechanisms of action was elucidated using quantitative polymerase chain reaction (Q-PCR) for comparative purposes.

There is clear rationale for the involvement of *RAD51C* and TP53 protein in the downstream events of a chemical exposure as both are involved in DNA damage and repair pathways but the involvement of *CSTA* is less apparent. Westerink *et al.* (2010) noted that the induction of *CSTA* is quite specific to genotoxicity although the LXR agonist Tularik 0191317 (Westerink *et al.*, 2010) and bile acids (Jones *et al.*, 1998) are also known to induce this anti-apoptotic protein.

RAD51C protein is well documented to be involved in homologous recombination after DNA double strand breaks which are either a primary or secondary effect of exposure to many carcinogenic compounds. Initially, RAD51 accumulates at the sites of DNA damage in order to direct the other members of the DNA repair pathway and is believed to promote DNA strand exchange. RAD51C has been detected in a number of protein complexes with other members of the family including a complex with RAD51B, RAD51D and XRCC2 and a second with XRCC3 (Liu *et al.*, 2004). There is evidence to suggest that RAD51C functions to resolve Holliday junctions that form to replicate DNA from the sister chromatid (Liu *et al.*, 2004; Sharan *et al.*, 2007). Defects in this gene have been found in families with a history of both breast cancer and ovarian cancer (Meindl *et al.*, 2010). *RAD51C* was also identified in a study which looked at the expression profiles of HEPG2 cells after exposure to cadmium, nickel and arsenic (Kawata *et al.*, 2009).

The 'guardian of the genome', *TP53*, is a tumour suppressor gene that encodes a pivotal protein in the response to DNA damage, mitotic spindle disruption and activation of oncogenes. Under non-stress conditions, the TP53 protein is a short-lived transcription factor. When cells are exposed to various forms of stress, it is activated by phosphorylation by checkpoint kinase Chk2 and then in turn binds to a TP53-responsive element in the promoter of target genes activating downstream target genes. Targets of the activated TP53 protein are found in cell-cycle arrest, DNA repair, senescence and apoptosis pathways (Powell *et al.*, 2014). Due to its critical function in maintaining the genomic stability of the cell, levels of TP53 protein are tightly regulated and the main mechanism of TP53 activation, in response to cellular stresses such as DNA damage, is through post-transcriptional activation (Lakin and Jackson, 1999). There is a transient increase in *TP53* mRNA levels which occurs as the cell transitions from G₀/G₁ phase of the cell cycle and into early S-phase in preparation for TP53 protein synthesis prior to DNA synthesis during the cell cycle (Boggs and Reisman, 2006; Takahasi *et al.*, 2011) and this has been hypothesised to be to ensure a rapid response to DNA damage before exiting S-phase (Takahasi *et al.*, 2011).

Cystatin A, also known as stefin A, is a cysteine protease inhibitor from family 1 of the cystatin superfamily (Keppler, 2006). It is found in the cytoplasm because, unlike other cystatins, it does not contain a signal peptide for secretion. High levels of expression have been reported in epithelium and lymph nodes

as well as the liver, spleen, keratinocytes and poly-morphonuclear granulocytes (Keppler, 2006; Barrett 1985, 1986). The cysteine protease family are involved in many biological functions including apoptosis, MHC class II immune responses, prohormone processing and remodelling of the extracellular matrix (Moffitt *et al.*, 2010). As such, cysteine proteases are important in maintaining the normal function of the extracellular matrix and are normally in balance with their inhibitors, the cystatins/stefins. There is growing evidence to suggest that in patients with malignant tumours the expression and activity of both the proteases and their inhibitors are altered (Li *et al.*, 2011).

CSTA has been suggested as an indicator of aggressive sub-types of prostate and breast cancer (Kuopio *et al.*, 1998; Sinha *et al.*, 1999) though generally the expression is lost during progression of lung, prostate, skin and breast cancer with the loss of the cells expressing *CSTA* (Keppler, 2006). It has been shown to be upregulated in the saliva of breast cancer patients and suggested as a possible specific biomarker (Zhang *et al.*, 2010). Protein expression of *CSTA* was predictive of laryngeal carcinoma and negatively linked to lymphatic metastasis, reoccurrence and survival (Li *et al.*, 2011). Increased immunostaining for *CSTA* was related to a favourable outcome in squamous cell carcinoma patients (Anicin *et al.*, 2013). A study by Jais *et al.* (2008) identified a 16-gene signature which included *CSTA* that predicted the survival rate of elderly patients with diffuse large B-cell lymphoma being treated with doxorubicin and a mixture of other drugs. Despite the lack of functional information on *CSTA*, the growing number of studies that have identified this gene as a potential biomarker for genotoxicity or the identification of various types of cancer suggest it may have future application in such fields.

In this study, the gene expression of *RAD51C*, *TP53* and *CSTA* in HEPG2 cells exposed to a range of genotoxic compounds was measured by Q-PCR amplification. In parallel, we developed an alternative assay for the same 3 gene signature based on chemiluminescence (Arnold *et al.*, 1989; Nelson *et al.*, 1996a,b) which we have used for gene expression analysis of abundant genes (Thomas-Jones *et al.*, 2003a, 2003b) and the identification of single nucleotide differences in RNA transcripts (Morris *et al.*, 2014). The chemiluminescence method allows the direct quantitation of RNA transcripts by the use of acridinium-ester (AE)-labelled complementary probes and is capable of analytical sensitivity of 10-50 attomol of target with a

routine coefficient of variance of less than 15% (Morris *et al.*, 2012). It consists of three sequential steps: hybridisation, where the probe forms a double stranded duplex with the target and the AE intercalates; hydrolysis, where any AE unprotected by intercalation is hydrolysed rendering it incapable of producing light; and detection, where the light output is triggered. Due to the chemical hydrolysis step, these assays have the ability to distinguish between targets differing by a single base pair allowing high specificity (Nelson *et al.*, 1996a, 1996b).

We have used this technology in past studies to directly measure highly abundance messenger RNA transcripts (eg. vitellogenin mRNA). Here we aimed to determine if this technology was capable of measuring medium abundance genes such as those that would be useful for a genotoxicity screen *in vitro* and also if it could, due to its reported low CVs, be adapted to detect trends of gene expression changes at lower concentrations of compound than Q-PCR amplification.

2. Materials and Methods

2.1 Human Gene/ Protein nomenclature

The gene and protein nomenclature used in this manuscript is that recommended by the HUGO gene nomenclature committee (Wain *et al.*, (2002)).

2.2 Materials

Standard chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA). Those used in HEPG2 exposures are listed in Tables 3 and 4. Specialised Q-PCR materials and molecular grade glycogen were supplied by Life Technologies (Carlsbad, CA, USA) except the Q-PCR enzyme buffer mix which was supplied by PCR-BIO (PCR BIO, London, UK).

Eurofins MWG Operon (Ebersberg, Germany) supplied all the oligonucleotides with the exception of the modified oligonucleotides. These were synthesised with an internal linker containing a free primary

amine attached to the oligonucleotide *via* a six carbon aliphatic spacer arm and were supplied by Integrated DNA Technologies (Coralville, IA, USA).

2.3 *Cell Culture and exposures*

All cell culture growth and exposures on the HEPG2 cell line were conducted by AvantiCell Science Ltd, Ayr, Scotland, according to conditions described below, including initial testing on compound concentration range and solubility. A test on the compound's solubility in DMSO was performed. For a number of compounds, the top concentration resulted in precipitation when diluted with culture medium for addition to the well. If any precipitation was observed, a range of solvents was tested to determine the optimal solvent.

2.4 *Cytotoxicity prescreen*

Once an appropriate solvent had been determined, a MTT cytotoxicity test was performed (data not shown). Human HEPG2 cells were cultured under standard growth conditions in a culture medium containing Minimum Essential Medium, heat inactivated foetal calf serum, glutamine, non-essential amino acids, fungizone, and antibiotics. Cells were seeded at an assay-optimised density in a 96 well plate format. Cells were at passage 16 at the time of assay.

Following 48 hours' incubation at 37°C and 5% CO₂, in relative humidity >95%, the cells were challenged for a 24 hour exposure period with 18 test compounds at 3 concentrations (n=3). The cytotoxicity assay is based upon measuring the leakage of cytosolic enzyme lactate dehydrogenase from dead or dying cells that have lost membrane integrity. Detergent-lysed cells were measured to provide the maximum value, which was then used to calculate % cytotoxicity induced by the test material. In addition to measuring the % cytotoxicity in response to each of the treatments, all cells were examined microscopically, and a visual observation was recorded (data not shown). Staurosporine (10 µM), a cell permeable inhibitor of protein kinases, was included as a positive control to demonstrate assay performance. Appropriate test compound vehicle controls were also included.

In summary, cytotoxicity was detected in response to 4 of the chemicals tested. Benzo(a)pyrene caused cytotoxicity at all three of the concentrations tested (100 μ M = 35%, 50 μ M = 30% and 25 μ M = 12%). Cadmium chloride caused cytotoxicity at all three of the concentrations tested (50 μ M = 53%, 25 μ M = 51% and 10 μ M = 30%). Arsenic (III) oxide was estimated to cause 19% cytotoxicity at 50 μ M but none was detected at 25 and 10 μ M. Cisplatin caused 21% cytotoxicity at 100 μ M. The concentration range was adjusted accordingly in the case of observed cytotoxicity, solubility issues (benzopyrene) or precipitation.

2.5 Genotoxicity testing

Human HEPG2 cells were cultured as described above. Cells were seeded at a density of 3.0×10^6 cells per culture well (6-well plates). Cells were at passage 17 at the time of sample harvest. Following 24 hours' incubation at 37°C and 5% CO₂, in relative humidity >95%, the cells were challenged with the 18 test compounds for a further 24 hour exposure period. For each test chemical, triplicate wells of HEPG2 cells were exposed to 4 concentrations. Triplicate measurements of a solvent control were included for comparison.

Following the 24 hour exposure period, the cell lysates were prepared by the following method. Media/test compound was removed and the cells were washed gently with 2 ml of sterile phosphate buffered saline (PBS). Care was taken to remove as much PBS as possible from the wells. The cells were lysed in RLT buffer (600 μ L) supplied by Qiagen (Venlo, The Netherlands), which was added to each well, then scraped vigorously with a sterile inverted pipette tip. The plate was tipped at an angle to collect as much sample as possible. Samples were collected into nuclease-free non-stick eppendorf tubes (Alpha Laboratories, Eastleigh, UK), containing 40 U of RNase inhibitor (RNase OUT, Life Technologies). The tubes were vortex mixed, placed on ice and stored at -80°C.

Two further exposures were done at a later date: the 4-chloroaniline exposure was repeated with a higher concentration (1000 μ M) and doxorubicin exposure was repeated (1 μ M) to gain more material for direct measurement experiments.

2.6 RNA extraction

The total RNA was extracted using the Qiagen RNeasy kit according to manufacturers' instructions and eluted in 50 µl nuclease-free H₂O and 40 U RNaseOUT (Life Technologies) was added before storage. Purity and concentration were assessed by measuring the absorbance at 260 nm on a Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA, USA).

A Bioanalyser 2100 (Agilent, Santa Clara, CA, USA) was used to confirm the integrity of the RNA from the benzopyrene exposure and an average RNA integrity number (RIN) of 7.8 was determined. To further validate the process, two hydroxymethylbilane synthase (*HMBS*) Q-PCR reactions were performed on the same cDNA and regression analysis was conducted and also *HMBS* and *GAPDH* expression were compared (data not shown). Both experiments showed good correlation ($R^2 > 0.9$) suggesting the RNA quality was acceptable and the Q-PCR methodology reproducible.

2.7 cDNA synthesis and Quantitative Polymerase Chain reaction (Q-PCR)

Total RNA (800ng) was reverse transcribed into single-stranded cDNA using the QuantiTect reverse transcription method according to manufacturers' instructions (Qiagen). A control which included all reaction components and RNA but no reverse transcription enzyme was included for each exposure to ensure there was no genomic DNA contamination present. The cDNA was diluted 1:10 in nuclease-free water before using 4 µL in a Q-PCR reaction with a total volume of 20 µL, containing 10 µL of 2 x qPCR BIO PROBE MIX LO-ROX (PCR BIO, London, UK), 1 µL of TaqMan probe primer mix (Life Technologies) and 5 µL of RNase free water (Ambion, Austin, Texas). The final concentration of each primer was 900 nM and of the 6-FAM™ dye-labelled TaqMan MGB probe was 250 nM. Thermocycling conditions were 95°C for 2 minutes, then 40 cycles of 95°C for 10 s, 60°C for 30 s. All PCR measurements were made in triplicate. TaqMan probes and primer sets were obtained from Life Technologies for the following genes (manufacturer's part numbers given in brackets): *RAD51C* (Hs00365220_m1), *CSTA* (Hs 00193257_m1), *TP53* (Hs 01034254_g1), *CYP1A1* (Hs01054797_g1). *HMBS* (Hs 00609293_g1) was measured as a control gene for

all samples. Where *HMBS* gene expression did not conform to the stringent criteria for use (see below), *GAPDH* (Hs02758991_g1) and 18S (Hs99999901_s1) were measured.

Q-PCR amplifications were performed on a Stratagene Mx3000P instrument (Agilent, Santa Clara, CA, USA) using a 96 well plate format. MxPro software (version 4.10) was used to adjust raw fluorescence readings by subtracting baseline background, normalizing against the ROX reference dye (dRn) and estimating the threshold to give C(t) values. Several acceptance criteria were applied to each run which must be met for the run to be considered valid: no amplification after 35 cycles in the no-template (NTC) or the no-amplification (NAC) controls and the average standard deviation (SD) of technical replicates within the experiment to be equal or less than 0.3 SD. If these criteria were not met, the experiment was repeated.

2.8 Acceptance criteria applied to control genes

The control gene data was examined for each exposure and a Student's t-test (two-tailed) applied to each condition against the solvent control. For a gene to be accepted as a control gene and used for data normalisation, it was essential two criteria were met: there must not be a two-fold difference (or greater) in expression over the range of concentrations used (Schmittgen and Livak, 2008) nor a statistically significant difference in gene expression.

For the majority of the exposed samples, hydroxymethylbilane synthase (*HMBS*: accession number NM_000190), the gene for a key enzyme in the haeme biosynthetic pathway, proved to be an appropriate control gene and was used to normalise the data. In the case of doxorubicin, nickel chloride, sodium dichromate, arsenic oxide and copper sulfate, two other control genes were investigated: 18S and *GAPDH*. The gene found to have the least variable expression for each individual compound according to the criteria detailed above was chosen for data normalisation.

2.9 Statistical treatment

The Q-PCR data were analysed by relative expression analysis as described in the paper by Schmittgen and Livak (2008) to generate $2^{-\Delta C(t)}$ values after normalisation against the most stable reference

gene and then the mean was expressed as a ratio against the solvent control (0 μ M). A two-tailed Student's t-test, was applied to each condition to identify statistically significant differences between the solvent control and the exposure samples.

2.10 Heat map and hierarchical clustering of genotoxic compounds based on their gene profiles

The gene profile at all concentrations was used to generate a heat map, from which hierarchical clustering analysis was performed. The data treatment was as follows: $2^{-\Delta C_t}$ values were calculated, and then the mean was expressed as a ratio against the solvent control value before \log_2 transformation. The hierarchical cluster analysis was performed using a one minus Pearson Correlation Coefficient with average linkage. Data analysis was performed with GENE-E software (Broad Institute, MA, USA). Software can be downloaded from <http://www.broadinstitute.org/cancer/software/GENE-E/download.html>.

2.11 Chemiluminescent AE-probe preparation

Probe sequences were designed by alignment of all isoforms found in Genbank using CLC Main workbench (version 6.9) from CLC Bio (Aarhus, Denmark), and selecting regions where all isoforms were conserved. The probe sequences are listed below (Table 1) and # designates the position of the linker. In all cases, the reverse complement sequence was used to make a dilution series for the standard curves.

Table 1
Sequences of modified probe oligonucleotides (# designates the position of the linker).

AE- labelled probes	
Hs RAD51C	5' GAA GCC CTG GG # TAT GCT CCT GCT C 3'
Hs TP53	5' CCC AAC TGT AGA AAC T # A CCA ACC CAC C 3'
Hs CSTA	5' GAT TTC TGG AGT # GGC GGG TTT GGC CTC AG 3'
Hs HMBS	5' CCC AGG CAT CT # GTG CCC CAC AAA 3'

2.12 Probe labelling and purification

Oligonucleotides were labelled with acridinium-ester (NHS-AE) through an internal amine linker and purified using high-performance liquid chromatography (HPLC) based on the procedures described in Nelson *et al.*, (1992) and Morris *et al.* (2014). HPLC purification was conducted using an instrument from Thermo

Separation Products (Waltham, MA, USA) with automatic gradient elution and equipped with a detector capable of measurement at 260 and 325 nm. The crude labelled oligonucleotide was subjected to purification by gradient elution IE-HPLC using a 4.0 x 125 mm Nucleogen-DEAE 60-7 column (Macherey-Nagel, Düren, Germany).

2.13 *Direct method of measuring chemiluminescence*

AE-labelled probe (1 pmol per reaction) was added to either ssDNA target or total RNA after dilution in 100 mM lithium succinate, 2 mM EDTA, 2 mM EGTA, 10% lithium lauryl sulfate pH 4.8 followed by hybridisation at 60°C for 30 minutes. A second reagent was added (150 mM sodium tetraborate, 5% Triton X102 pH 8.5.) followed by a further 15-20 minutes at 60°C. The temperature was reduced to 4°C and remaining chemiluminescence was measured over 2 s using a Leader 50i luminometer (tube based) (Gen-Probe, San Diego, CA, USA) with sequential injections of 32 mM hydrogen peroxide in 1 mM nitric acid followed by 1.5 M NaOH. For quantitation, a standard curve of reverse complementary ssDNA target was also measured.

The plate format was essentially as described above except the probe concentration was 100 fmol per reaction, the hybridisation and hydrolysis incubations were performed at 65°C on a Techne PCR instrument (Bio-Techne, Minneapolis, MN, USA) with a heated lid at 110°C and a Centro Luminometer LB960 (96-well plate format, Berthold Technologies, Bad Wildbad, Germany) with MikroWin software (Version 4.41) was used to measure the light output.

2.14 *Linear amplification step prior to chemiluminescence measurement*

For the first strand cDNA synthesis, the following reaction was set up for each RNA sample to be analysed: RNA (1 µg) and nuclease-free H₂O to a total volume of 5 µL, then 2 µL dNTPs (10 mM, ClonTech UltraPure), 1 µL each of MPXForward primers (RAD51C-MPXF, CSTA-MPXF, TP53-MPXF, HMBS-MPXF) and of MPXReverse primers each (RAD51C-MPXR, CSTA-MPXR, TP53-MPXR, HMBS-MPXR). Primers were diluted to

a concentration of 100 pmol/ μ L prior to use and sequences are given in Table 2. An additional sample was included as a background control (cycle 1 (C1) control).

Thermocycling conditions were one cycle of 65°C, 5 min, 60°C 3 min, 55°C 3 min, 50°C 60 min then 70°C 15 min in a Techne PCR machine (heated lid at 110°C). During the 50°C step, 8 μ L of a mix consisting of 4 μ L 5x First strand buffer (250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl₂), 2 μ L dithiothreitol (0.1 M stock, 8 mM final concentration), 40 U RNase OUT and 200 U of Superscript III was added to each reaction and mixed gently by pipetting.

To the sscDNA, 50 μ L 2 x AmpliTaq Gold 360 mastermix, 49 μ L nuclease-free H₂O and 2 U of RNase H were added, mixed then the following thermocycling conditions were used to synthesise double stranded cDNA: 37°C 20 min, 95°C 10 min, 57°C 5 min, 72°C 30 min. One sample was removed after the first complete cycle (C1) and placed on ice, then cDNA was linearly amplified with a further 14 cycles of 95°C 30 s, 57°C 30 s, 72°C 2 min. All components were sourced from Life Technologies except where indicated.

The dscDNA (8 μ L) was used in a chemiluminescent detection assay as described above for the plate format except it was heated to 95°C for 5 minutes before adding AE-labelled probe. The RLU value of the C1 control was subtracted from the data.

Table 2
Sequence of the human multiplex primers used for linear amplification.

Multiplex primers	Forward (-MPXF)	Reverse (-MPXR)
CSTA	5' CCA CAC TTC CCT GTT CAC TT 3'	5' CAG CTC GTC ATC CTT GTT TTT 3'
RAD51C	5' AGC GGG ATT TGG TGA GTT T 3'	5' ACT CCA CCC CCA AGA ATA TCA 3'
TP53	5' ACA TCT GGC CTT GAA ACC 3'	5' AAA GAA ATT GAC CCT GAG CA 3'
HMBS	5' ACG GCT CAG ATA GCA TAC AA 3'	5' ATA GCA GTG AGA ATG GGG CA 3'

3. Results

We measured the changes induced in a 3 gene signature in HEPG2 cells in response to 16 genotoxic and 2 non-genotoxic non-carcinogenic chemicals (n=18) with different mechanisms of action. The chemicals

were chosen to give 7 compounds with well-characterised genotoxic mechanisms from Group 1 of the recommended list of genotoxic chemicals (Kirkland *et al.*, 2008). A further 8 compounds were chosen that were not present in the Kirkland recommended list nor in the Westerink study (Westerink *et al.*, 2010), which tested over 200 compounds in total. The 8 compounds were chosen to have a wide range of mechanisms and were very diverse, including metal salts to endocrine disrupting compounds, and so had a less well defined mode of action with regard to genotoxicity. Two chemicals, (±)-menthol and phthalic anhydride, were chosen to act as negative controls from Group 3 of non-carcinogens; these are negative or equivocal for genotoxicity *in vivo* and show no carcinogenicity in rat and mice studies (Kirkland *et al.*, 2008) and doxorubicin was included as a positive control (Westerink *et al.*, 2010).

The starting point for determining the concentration range for the exposures was taken from the literature (Westerink *et al.*, 2010; McElwee *et al.*, 2009; Song *et al.*, 2009; Verma *et al.*, 2011; Osterburg *et al.*, 2010; Wang *et al.*, 2009; Wang *et al.*, 2013; Kuzbari *et al.*, 2013; Konac *et al.*, 2005; Permenter *et al.*, 2011; Kawata *et al.*, 2009; Chin *et al.*, 1994; Hodges *et al.*, 2004; Hu *et al.*, 2004; Muller *et al.*, 2005). Where possible, several concentrations below the lowest observed effect concentration were examined to provide a stringent test of sensitivity for the different assays tested. A test of solubility and cytotoxicity were performed and Table 3 shows the actual concentrations and solvents used in the exposure experiments.

Table 3
List of compounds with their associated solvents.

Compound	CAS no.	vehicle control	Dose 1 (μM)	Dose 2 (μM)	Dose 3 (μM)	Dose 4 (μM)
Doxorubicin	25316-40-9	0.01% DMSO	0.05	0.1	0.5	1
(\pm) Menthol	15356-70-4	0.5% DMSO	1	10	100	1000
Phthalic anhydride	85-44-9	0.5% DMSO	1	10	100	1000
Benzopyrene	50-32-8	0.625% Acetone	3.125	6.25	12.5	25
7,12-Dimethylbenzanthracene (DMBA)	57-97-6	0.25% DMSO	1	5	10	50
2-(Acetylamino)fluorene (2-AAF)	53-96-3	0.5% Acetone	50	100	250	500
Cadmium chloride	10108-64-2	0.05% DMSO	0.1	0.5	1	5
Cisplatin	15663-27-1	0.05% DMSO	1	5	10	50
4-Chloroaniline (first expt)	106-47-8	0.5% DMSO	10	50	100	500
4-Chloroaniline (second expt)	106-47-8	0.5% DMSO	NA	NA	NA	1000
2,4-Diaminotoluene	95-80-7	0.5% DMSO	10	50	100	500
Nickel (II) chloride	7791-20-0	H ₂ O	10	50	100	500
Sodium dichromate	7789-12-0	H ₂ O	5	10	50	100
Arsenic (III) oxide	1327-53-3	0.1% NaOH	1	5	10	50
Lead (II) acetate	6080-56-4	H ₂ O	5	10	50	100
Sodium tungstate	10213-10-2	H ₂ O	50	100	500	1000
Copper sulfate	7758-98-7	H ₂ O	10	50	100	500
Hydroxyurea	127-07-1	H ₂ O	10	50	100	500
Diethylstilbestrol	56-53-1	0.05% MeOH	1	5	10	50

3.1 RNA concentration

There was no statistically significant difference in the concentration of total RNA in the solvent control (0 μM) compared to RNA extracted from exposed HEPG2 samples for most chemicals in this study, suggesting that, in general, the chemicals chosen had no effect on global transcription based on a Student's t-test, two tailed between the solvent control and each concentration of compound used in the experiment). There were three exceptions to this (Fig. S1). As sodium dichromate concentration increased to 50 μM and above, the concentration of RNA decreased (one-way ANOVA, $p = 0.0008$) suggesting decreased transcription. Doxorubicin had a complex trend over the concentrations in this study with an initial increase and then a decrease (one-way ANOVA, $p = 0.0039$) which only reached significance at 0.1 μM (Student's t-

test against the solvent control). However, copper sulfate showed a striking decrease in RNA concentration over all four concentrations compared to the solvent control suggesting a large impact on global transcription (one-way ANOVA, $p = 4.58E-06$). To normalise for any global effect on RNA transcription, a standard amount of RNA (800ng) was used in cDNA synthesis.

3.2 Gene expression analysis using Q-PCR

The gene expression of *RAD51C*, *TP53* and *CSTA* was measured, using Q-PCR based on TaqMan primers and FAM-probes in an *in vitro* system based on the human liver carcinoma cell line, HEPG2. Overall, the Q-PCR results showed excellent technical replication, with an average standard deviation of ≤ 0.1 (0.3% coefficient of variance (CV)) and an average inter-sample CV of 23%.

The trends in gene expression for each compound are shown in Fig. 1, 2 and 3. Two chemicals were included in the study as good examples of non-genotoxic non-carcinogenic chemicals based on the recommendations of Kirkland *et al.* (2008): phthalic anhydride and menthol (Fig. 1A & B). Our study showed no trend of dysregulation of gene expression for the four genes (Table 4) over a wide range of concentrations (0, 1, 10, 100 and 1000 μM) for either of these chemicals.

Doxorubicin (DOX) was included in the study as previous studies have reported a strong response to genotoxic insult (Westerink *et al.*, 2010) (Fig. 1C). This was confirmed for DOX exposure in this study with a strong change in gene expression for all three genes with increasing concentration. This was despite the use of lower concentrations of DOX than any other compound in the study.

Position for Figures 1, 2 and 3 (provided separately)

Figure 1, 2, 3. Q-PCR analysis of 3- gene signature. Relative gene expression (log2 transformation of the genes after normalisation) plotted against the concentration of the chemicals (μM). The symbol \blacksquare designates *RAD51C* expression, \blacktriangle *TP53*, \bullet *CSTA*, \blacklozenge *HMBS*, \times *GAPDH* / 18S. **Figure 1** shows three compounds expected from previous studies to give a clear genotoxic

(doxorubicin) or non-gentoxic result (menthol and phthalic anhydride). **Figure 2** shows seven compounds included in the Kirkland list of genotoxic compounds. Results from two separate experiments are shown for chloroaniline. **Figure 3** shows a further eight compounds not included in the Kirkland list.

Table 4
Overview of the gene expression changes detected using Q-PCR for the chemicals included in the study.

Compound Designation	Compound Name	Q-PCR		
		<i>RAD51C</i>	<i>TP53</i>	<i>CSTA</i>
Non-genotoxic non-carcinogenic (Kirkland <i>et al.</i> , (2008))	(±) Menthol			
	Phthalic anhydride			
Positive control (Westerink <i>et al.</i> , 2010)	Doxorubicin			
Genotoxic chemicals (Kirkland <i>et al.</i> , (2008))	Benzopyrene			
	7,12-Dimethyl-benzanthracene			
	2-(Acetylamino)fluorene			
	Cadmium chloride			
	Cisplatin			
	4-Chloroaniline (first expt)			
	4-Chloroaniline (second expt)			
	2,4-Diaminotoluene			
Less well defined mode of action with regards to genotoxicity	Nickel chloride			
	Sodium dichromate			
	Arsenic oxide			
	Lead acetate			
	Sodium tungstate			
	Copper sulfate			
	Hydroxyurea			
	Diethylstilbestrol			

Legend: Table 4 shows the difference in the gene expression between the solvent control (0 µM) and the highest concentration tested (Student's t-test, $p \leq 0.05$). Dark grey designates a statistically significant difference and light grey designates no statistically significant difference.

Across the study, most compounds with a positive response affected the expression of more than one gene (Table 4). Ten compounds affected the expression of *CSTA* whereas seven affected *TP53* or *RAD51C* expression. Only four compounds showed changes in one target gene – BaP and chloroaniline (*TP53*) and nickel chloride and 2-(acetylamino)fluorene (*CSTA*), suggesting a weaker response; this was also suggested by the higher concentration required of two of these compounds to stimulate a response (chloroaniline: 1000 μ M and 2-(acetylamino)fluorene: 500 μ M). The fact that the majority of compounds showed a change in at least one of these three genes, despite the stringency of the exposure test, suggests that this 3-gene signature has potential as an indicator for genotoxicity for a variety of mechanisms of action.

A number of compounds show a statistically significant *RAD51C* increase suggesting direct DNA damage and the subsequent induction of the DNA damage repair pathways (Table 4). These include doxorubicin (Fig 1C), cisplatin (Fig 2D) and hydroxyurea (Fig 3G) and to a lesser degree cadmium chloride (Fig 2C). Initial increases in *RAD51C* expression were replaced by decreases in higher concentrations for sodium dichromate (Fig 3B), arsenic oxide (Fig 3C) and copper sulfate (Fig 3H), suggesting inhibition of DNA repair.

The mechanism of *TP53* activation is well established as being post-translational (Lakin and Jackson, 1999). However, this study detected some statistically significant changes in *TP53* RNA expression: the following p values were derived from a Student's t-test between the solvent control and the highest concentration of compound used in the experiment. There were very modest changes in expression with BaP (1.69 fold, p = 0.03), DOX (1.28 fold, p = 0.03) and chloroaniline (1.21 fold, p = 0.04). More strikingly, we also found evidence of decreased transcription in the presence of diethylstilbestrol (0.73 fold, p = 0.001), sodium dichromate (0.27 fold, p = 0.001), arsenic oxide (0.08 fold, p = 0.001) and at the three highest concentrations of copper sulfate (50, 100 and 500 μ M), reaching a maximum decrease at 0.16 fold (p = 0.0008). All of these exposures were checked for cytotoxicity before use, and of the compounds that changed *TP53* expression, only benzopyrene and arsenic showed some evidence of cytotoxicity at the highest dose. Benzopyrene was estimated to cause 12% cytotoxicity at 25 μ M and arsenic (III) oxide was estimated to cause 19% cytotoxicity at 50 μ M though none was detected at 25 and 10 μ M. There was no cytotoxicity detected with any of the other compounds that changed *TP53* expression. The *TP53* protein

requires zinc for normal protein folding into a conformation capable of specific DNA binding (Meplan *et al.*, 2000). The presence of 30 μ M copper is sufficient to displace zinc and cause an abnormal conformation and altered transcriptional properties (Hainaut *et al.*, 1995, Tassabehji *et al.*, 2005). There have been previous reports of altered *TP53* mRNA expression in response to copper (VanLandingham *et al.*, 2002; Narayanan *et al.*, 2001; Obata *et al.*, 1996; Tassabehji *et al.* 2005.; for a review see Phatak and Muller, 2015).

CSTA dysregulation was the single most effective indicator in this study, changing in the presence of 10 out of 16 compounds studied (4 out of 8 known genotoxic agents). This is in contrast to the findings of Westerink *et al.* (2010) who found that the HEPG2 p53_luc reporter assay had the highest sensitivity both across 62 compounds tested (85%, ECVAM (European Centre for the Validation of Alternative Methods) compound set) and also across the same compounds used in this study (8 out of 8 compounds, (including doxorubicin) gave a positive result compared with 6 and 5 for the HEPG2 cystatin A_luc and RAD51C_luc reporter assays respectively), though this may reflect the differences in methodology, *e.g.* four TP53-responsive elements were used to construct the TP53-luciferase reporter constructs. In this study, *CSTA* expression reached 294-fold for doxorubicin and 12.7-fold for cisplatin relative to the expression levels in the absence of compound.

Some of the strongest responses seen for the different compounds were found with the set that contained metal salts, which changed the expression of all genes examined. Sodium dichromate and arsenic oxide showed initial increases in gene expression at the two lower concentrations followed by a marked decrease. Copper sulfate however, changed *CSTA* expression by 3.43 fold ($p = 0.004$) and expression of *RAD51C* by 0.35 fold ($p = 0.0003$) and *TP53* by 0.16 fold ($p = 0.0008$).

However, two compounds (7,12-dimethylbenzanthracene and 2,4-diaminotoluene) did not show a significant dysregulation of the 3-gene signature and two (benzopyrene and 2-(acetylamino)fluorene) did not show as strong a response as expected despite the use of concentrations comparable to those used in the Westerink study (2010). A common feature of these four compounds is that they all require metabolic activation before causing toxicity. A number of PAH compounds are metabolised by CYP1A1 including

benzopyrene and 2-(acetylamino)fluorine (Muñoz and Albores, 2011). The expression of several genes required for detoxification and metabolic activation, *GST2A*, *GADD45α* and *CYP1A1*, was confirmed in the HEPG2 cell line (data not shown). The expression of *CYP1A1* in response to benzopyrene was measured by Q-PCR and found to increase with increasing concentration as expected (168 fold at 25μM, $p = 2.8E^{-05}$, data not shown). This suggests to us that the reason for the underlying difference between the two studies is not the ability of the cells to respond to the compound nor the batch of chemical used but is due to methodological difference, for example measurement of native gene expression compared to the reporter gene approach utilised by the Westerink study.

3.3 Hierarchical cluster analysis of the Q-PCR results

To organise the compounds into categories with similar gene profiles, a heat map was generated with GENE-E, a matrix visualisation and analysis platform, followed by hierarchical clustering. The hierarchical cluster analysis was performed using a one minus Pearson Correlation Coefficient with average linkage (Fig. 4). The clustering suggested two major groups. The first group contains the non-carcinogenic chemicals menthol and phthalic anhydride and a cluster of compounds that caused changes in 2 or 3 genes. Group 2 contained compounds with more complex profiles where both increases and decreases within an expression profile were observed.

Figure 4: Heat map and hierarchical clustering of genotoxic compounds based on their gene profiles.




Figure 4: Heat map and hierarchical clustering of genotoxic compounds based on Q-PCR gene profiles. The gene profile at all concentrations was used to generate a heat map, from which hierarchical clustering analysis was performed in order to categorise the compounds with similar characteristics. The hierarchical cluster analysis was performed using a one minus Pearson Correlation Coefficient with average linkage. Data analysis was performed with GENE-E data visualisation software. The horizontal axis of the dendrogram (tree diagram) represents the distance or dissimilarity between clusters. The intensity of the red and blue colour indicate high and low expression levels, respectively, relative to the mean (see scale bar) up to a maximum of +3 or -3 fold. Details of the concentrations of each compound used are shown in Table 1. CTR designates the solvent control data (0 μ M) for each experiment. * designates the cluster discussed in the results section.

The hierarchical clustering suggested a close relationship between the gene profiles of doxorubicin and cisplatin, both compounds that directly interact with and damage DNA by either intercalating within it or forming DNA adducts (Tacar *et al.*, 2012; Chu, 1994). These belonged to a larger group of clustered compounds (cluster designated by * on Fig 4), which also included a cluster of cadmium chloride, hydroxyurea and lead acetate. With this group of compounds, expression of both *RAD51C* and *CSTA* increased with increasing concentration but cadmium chloride, hydroxyurea and lead acetate had a general trend of decreasing *TP53* expression rather than the increase measured for doxorubicin and cisplatin (though few of the trends in *TP53* expression reached statistical significance). Underlying this is a different mechanism of action; the literature suggests predominantly an indirect mechanism of DNA damage for cadmium chloride (*via* oxidative stress and apoptosis (Waisberg *et al.*, 2003)), hydroxyurea (oxidative stress *via* base oxidation (Sakano *et al.*, 2001, Kovacic, 2011)) and lead acetate (associated with increased reactive oxygen species (ROS) production (Hernandez *et al.*, 2009)), as opposed to the direct DNA interaction of doxorubicin and cisplatin.

This analysis suggested that there might be many trends of perturbed gene expression at lower concentrations, which only reached statistical significance at the highest concentrations of compound, *i.e.* only relatively large changes of expression were identified as statistically significant. Assay sensitivity is therefore a limiting factor and could potentially be improved by a technology with less associated measurement error. We investigated a technology based on a chemiluminescent acridinium-ester, which is capable of measuring RNA transcripts directly and has high reported accuracy (low coefficient of variation (CV)). The chemiluminescent method is capable of detecting and quantitating RNA transcript concentration directly from RNA with no need to convert to cDNA nor is an amplification step required, making it quicker and easier to use. A specialist dual injection luminometer is required but all other reagents and equipment needed are available in the average molecular biology laboratory. An added advantage is that as this technology uses no enzymic steps, it has potential to provide a quicker, cheaper and more robust method for measurement of gene expression over those that do.

3.4 Chemiluminescent detection assay analysis:

Probes were designed for *CSTA*, *TP53*, *RAD51C* and *HMBS*, synthesised with a non-nucleotide amino linker and labelled with acridinium ester. Initially, the assay was performed in a tube based format using a Leader 50i luminometer as described in the Materials and Methods. Briefly, the AE probe is hybridised to the target for 30 minutes at 60°C followed by chemical hydrolysis of any unbound probe for 15-20 minutes. The performance of each probe was tested by measuring a dilution series of an oligonucleotide of the reverse complement sequence in triplicate (1000 – 0.1 fmol). The performance of a representative assay designed to measure *CSTA* is shown in Figure 5A and B and the performance characteristics are summarised in Table 5. The inter-assay variation for the *CSTA* assay was ~10% coefficient of variance (CV) (Table 5). A similar average inter-assay variation was estimated for the other assays (10.4% CV). The limit of detection (LOD), which was defined as the lowest quantity of the target oligonucleotide that can be distinguished from the absence of that oligonucleotide using a Student's t- test ($p \leq 0.05$), was 0.5 fmol, in the presence of 1 pmol of AE-probe.

Figure 5: Optimisation of the CSTA chemiluminescent detection assay.




Figure 5. Optimisation of the chemiluminescent detection assay. Panels A, B C and D: The performance of all AE-probes was characterised by measuring a dilution series of reverse complementary DNA oligonucleotide (target) and the results of a representative CSTA AE-probe, are shown. Panels A and B show the tube format and Panels C and D the 96-well format. Panels A and C show the linear regression analyses of the data over a range of 0.01 to 10 fmol target whereas Panels B and D show the data after log₁₀ transformation (log RLU vs log DNA oligonucleotide concentration). Panel E shows optimisation of CSTA AE-probe concentration (0.5, 0.1 and 0.05 pmol AE-probe) using a serial dilution of a reverse complement oligonucleotide (0.1, 0.5, 1, 5, 10, 100 and 1000 fmol). Panel F To determine if the 96-well format assay could measure CSTA transcript in total RNA, HEPG2 cells were exposed to doxorubicin (0 and 1µM) and total RNA extracted. The CSTA AE-probe (100 fmol per reaction) was used to measure CSTA expression directly in 5µg of HEPG2 RNA. ND designates 'not detected'.

Table 5
Performance of the chemiluminescent assay for *CSTA* (average values from three experiments).

Format	Intra-assay variation (CV%)			Average Inter-assay CV (%)
	EXPT 1	EXPT 2	EXPT 3	
Tube	9.3	9.6	10.5	9.8
Plate	17.0	15.4	11.4	14.6

With the tube format, there was appreciable evaporation at 60°C, which limited the range of temperatures that could be used for the hybridisation and hydrolysis steps. The format was then further optimised to a 96-well plate format using the Centro Luminometer LB960 which allowed for higher throughput as well as for higher temperatures to be used (the assay was performed in a PCR instrument with a heated lid at 110°C to prevent condensation). The temperature of both hybridisation and hydrolysis steps was increased to 65°C.

The performance of the plate format was characterised and shown to be sensitive and capable of quantitative measurement over 4 orders of magnitude (Fig. 5C and D). Each probe was tested with different probe concentrations to determine the optimal sensitivity and the results for the *CSTA* assay are shown in Figure 5E. The sensitivity of the assay improved with the lower concentrations of probe but the dynamic range of the assay also decreased. As expected, as the target concentration passed that of the probe, the light output (Relative Light Units) reached a plateau and further increases of target concentration no longer resulted in an increase in RLU. These changes led to an improvement in the assay sensitivity with assays having a limit of detection of 0.1 fmol and often as low as 10-50 attomol. The intra-assay variation from three representative *CSTA* assays was ~15% CV (Table 5).

3.5 Direct measurement of RNA transcripts with chemiluminescent probes

The Q-PCR data indicated that exposure of HEPG2 cells with 1 μ M doxorubicin (DOX) caused a ~300 fold change in the expression levels of cystatin A transcript. A second DOX exposure (0 and 1 μ M) was performed to determine if direct chemiluminescent measurement, *i.e.* directly from the RNA with no further manipulation, was capable of measuring the *CSTA* transcript. The limit of detection for this assay was determined to be 50 attomol of DNA oligonucleotide. As can be seen from Fig. 5F, *CSTA* transcript was below the limit of detection of the assay in total RNA (5 μ g) from HEPG2 cells. However, in total RNA from HEPG2 cells exposed to 1 μ M DOX, there was a detectable signal indicating an increased amount of measurable *CSTA* RNA transcript equating to ~0.2 fmol target. The expression of the other genes could not be detected with this format (data not shown).

To address the sensitivity of the assay, a linear multiplex amplification step of the RNA transcripts (*RAD51C*, *TP53*, *CSTA*, *HMBS*) was optimised. In this procedure, the RNA was converted to double stranded cDNA before undergoing a defined number of cycles of amplification then the amount of target present was measured using the chemiluminescent assay as described previously with the addition of an initial 95°C heat step to denature the dscDNA before hybridisation to the AE-probe. The minimal number of cycles of

amplification required to give an amount of cDNA measurable by the chemiluminescent detection assay was determined to be 15 (data not shown).

3.6 Amplified measurement of gene expression using chemiluminescent probes

To measure the gene expression, total RNA (1µg) from the initial DOX exposure was reverse transcribed into dsDNA and then amplified for 15 cycles before being hybridised with AE-labelled probes targeted to the 4 genes of interest (Fig. 6). The results confirmed that doxorubicin at very low concentrations caused clear changes in gene expression of this 3-gene signature (Fig. 4). *RAD51C* and *CSTA* showed a statistically significant increase in expression (Student's t-test, $p \leq 0.05$) showing general agreement between the two technologies. The *CSTA* measurements showed significant increase for all 4 concentrations, as demonstrated by Q-PCR. However, an increase of *RAD51C* was detected only for the 2 highest concentrations contrasting to an increase detection for all 4 concentrations with Q-PCR amplification. A modest change of *TP53* expression reaching a maximum of 1.28 fold ($p = 0.03$) was detected in the two highest concentrations using Q-PCR; however this was not detected by the chemiluminescent detection assay (CLA, 0.95 fold, $p = 0.3$). The comparative analysis of the three technologies is shown in Table 6 and shows the performance of the two amplification techniques to be similar (15 and 16% CV, respectively, Table 6). However, the maximum CV observed in the experiment was 49% for the amplified samples when using the CLA technology, higher than the 29.6% seen with Q-PCR. When the RNA was measured directly, *i.e.* no amplification step, a lower average CV of 10 % was estimated (Table 6).

To our knowledge, this is the first time the technology has been shown to be capable of quantitatively measuring messenger RNA transcripts that are of medium abundance equivalent to the majority of mRNA transcripts present in the cell. This technology has been used previously with a transcription mediated amplification (TMA) step to measure RNA targets in a qualitative fashion or directly to measure highly abundant transcripts (Thomas-Jones et al., 2003a, 2003b; Morris et al., 2014). Teaming this technology with a linear amplification step has a number of consequences; it adds enzymic steps increasing the cost, time to result and observed CVs but it lowers the limit of detection and by doing so, increases the

Figure 6: Measurement of the 3-gene signature after doxorubicin exposure of HEPG2 cells with the amplified chemiluminescent detection method.




Figure 6. Measurement of the 3-gene signature after doxorubicin exposure of HEPG2 cells using the amplified chemiluminescent method. RNA (1ug) for doxorubicin exposed HEPG2 cells was reverse transcribed to dscDNA then amplified for 15 cycles followed by measurement of the 3-gene signature with the chemiluminescent assay. Relative gene expression ($2^{-\Delta C(t)}$ values calculated after normalisation expressed as a ratio against the solvent control (0 µM)) is shown against doxorubicin concentration (µM) ± standard error of mean (SEM). The * symbol designates a statistically significant difference (Student's t-test, $p \leq 0.05$).

number of genes that can be measured to an extent that it is now a viable option for research with *in vitro* cell lines.

In general, the chemiluminescent assay results reflect the changes determined using Q-PCR though the latter method detected statistically significant gene expression changes in lower doses suggesting it is a more sensitive technique. However, the broad agreement of the amplified chemiluminescent method with the gold standard method, Q-PCR, suggests that this method may have utility in the future and broaden the use for chemiluminescent methods. Further optimisation of the new technique may improve both the sensitivity and the precision of the assay.

Table 6
Inter-assay variation for the doxorubicin exposure.

	Average CV (%)	Minimum CV (%)	Maximum CV (%)	No. of assays
Q-PCR	15	5.8	29.6	5
CLA [#] (amplified)	16.1	1.0	49.0	4
CLA [#] (direct)	10	8.7	11	1

[#] CLA designates chemiluminescent assay

4. Discussion

Our study confirmed that the 3-gene signature could be measured directly in exposure studies of a human hepatoma cell line, HEPG2. This was despite using an exposure range that was designed to be challenging. We found that *CSTA* expression was dysregulated by the largest number of compounds, demonstrating a significant change in 10 out of 16 compounds included in this study. For a few chemicals, the increase in *CSTA* expression was surprising, reaching 12.7 fold for the highest concentration of cisplatin and 294 fold for doxorubicin. The implications of a massive alteration in cytoplasmic *CSTA* protein levels are hard to decipher but may be an attempt to form a protective environment against the cysteine proteases involved in the apoptotic pathways (Jones *et al.*, 1998). Doxorubicin (DOX) is an anthracycline drug used in cancer chemotherapy that works by intercalating DNA, disrupting DNA replication, disrupting the cell cycle and causing DNA damage which ultimately leads to the triggering of the apoptosis pathway in rapidly dividing cells (Tacar *et al.*, 2012). DOX causes an apoptotic effect by up-regulating the apoptotic marker, Bcl-

2-associated X protein (Bax) expression (Tacar *et al.*, 2012; El-Moselhy and El-Sheikh, 2014). This leads to downstream activation of the caspases and ultimately apoptosis. The main cytotoxicity mechanism for cisplatin is to form DNA inter- and intra-strand crosslinks though it does also interact directly with RNA and protein (Chu, 1994). The damage triggers apoptosis *via* the intrinsic pathway at least in part by TP53 activation and by inducing the BAX gene and the downstream caspases. This could explain the strong induction of *RAD51C* (as part of the DNA repair pathway) and *CSTA* (as an inhibitor of cysteine proteases) caused by exposure to these two compounds seen in this study.

CSTA is known to inhibit UVB-induced apoptosis caused by caspase 3 in keratinocytes (Takahashi *et al.*, 2007). A study on rat hepatoma cell line provides evidence that *CSTA* reduces apoptosis induced by bile salts through the interaction with cysteine proteases such as cathepsin B but not caspase 3 and the authors suggest that mechanistically cathepsin B is downstream from the caspases (Jones *et al.*, 1998). This raises the possibility that the increase of a specialised member of the family which lacks the secretion peptide is an attempt by the cell to protect against damage by proteases.

We have previously used the chemiluminescent detection assay, which is based on specific hybridisation of oligonucleotides labelled with acridinium-ester, to measure directly high abundance genes such as vitellogenin, zona radiata proteins and beta actin (Thomas-Jones *et al.*, 2003 a,b). Here we demonstrate that the chemiluminescent assay can be adapted to measure genes with much lower levels of expression. In the Q-PCR workflow, cDNA synthesis is considered to be the least efficient step of the process and gene expression studies might be greatly enhanced if this step could be removed. Here we show that, in some circumstances, the changes in expression of an averagely abundant gene, *CSTA*, can be detected without the need for cDNA synthesis or amplification. The ability to measure RNA transcripts directly and accurately without the need for expensive and time-consuming steps may find application. Addition of a linear amplification step in order to quantify amplified products may also increase the utility of this technology. However, the disadvantage of introducing any form of target amplification is the probability of increasing the error associated with measurement and as such, the precision of the assay decreases.

This modified format may increase the types of application suitable for this technology, hence increasing its utility. The confirmation that the addition of a linear amplification step into the chemiluminescent assay is still capable of quantitative measurements is an important extension of the capability. Our study demonstrates that this novel method of measuring gene expression is capable of generating similar data to the gold standard technology, Q-PCR, and suggests that this adapted method may broaden the use for chemiluminescent methods.

Acknowledgments

This study was supported by funding from the Welsh Government under the CIRP A4B scheme [A4B2122TF]. In addition, PK was a co-inventor of a patent 'Genetic Biosensors using Chemiluminescence' (European patent 00971618.4), and PK and CM were co-inventors on a patent 'Detection of short non-coding RNA using chemiluminescence labelled nucleic acid probes' (GB1320560.4). A director of Invitron, Professor Stuart Woodhead and, in their roles as the Directors of CatCelt, Professor Keith Smith and Gamal El-Hiti advised on the technology and experimental design as part of the oversight committee. Invitron loaned equipment for part of the experimental work. We would especially like to thank Drs. Colin J. Wilde, Tracey Duff and Austin Logan at AvantiCell Science Ltd, Ayr, Scotland, for conducting the cell line exposures and for their helpful advice and feedback. We would also like to acknowledge Mike O'Reilly for his technical advice on HPLC purification and Ms Joan Hubbard for her technical assistance through the work. G. A. El-Hiti extends his appreciation to the Deanship of Scientific Research at King Saud University for its funding for his research through the research group project RGP- 239.

References

- Anicin, A., Gale, N., Smid, L., Kos, J., Strojan, P., 2013. Expression of stefin A is of prognostic significance in squamous cell carcinoma of the head and neck. *Eur. Arch. Otrhinolaryngol.* 270, 3143–3151.
- Arnold, L.J., Hammond, P.W., Wiese, W.A., Nelson N.C., 1989. Assay formats involving acridinium-ester-labeled DNA probes. *Clinical Chemistry* 35, 1588-1594
- Barrett A.J., 1985. The cystatins: small protein inhibitors of cysteine proteinases. *Prog. Clin. Biol. Res.* 180, 105–116.
- Barrett A.J., 1986. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. *Biomed. Biochim. Acta* 45, 1363–1374.
- Boggs, K., Reisman, D., 2006. Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter. *Oncogene* 25, 555–565.
- Chin, Y., Snow, E.T., Christie, N.T., 1994. The stimulatory effect of nickel chloride on DNA replication in human Hela Cells and *Escherichia coli*. *Carcinogenesis* 15, 1013–1016.
- Chu, G., 1994. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. *J. Biol. Chem.* 269, 787–790.
- El-Moselhy, M.A., El-Sheikh, A.A.K., 2014. Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. *Biomed. Pharmacother.* 68, 101–110.
- Hainaut, P., Rolley, N., Davies, M., Milner, J., 1995. Modulation by copper of p53 conformation and sequence-specific DNA-binding: role for Cu(II) Cu(I) redox mechanism. *Oncogene* 10, 27–32.
- Hernandez, L.G., van Steeg, H., Luijten, M., van Benthem, J., 2009. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. *Mutat. Res.* 682, 94–109.
- Hodges, N.J., Smart, D., Lee, A.J., Lewis, N.A., Chipman, J.K., 2004. Activation of c-Jun N-terminal kinase in A549 lung carcinoma cells by sodium dichromate: role of dissociation of apoptosis signal regulating kinase-1 from its physiological inhibitor thioredoxin. *Toxicology* 197, 101–112.
- Hu, T., Gibson, D.P., Carr, G.J., Torontali, S.M., Tiesman, J.P., Chaney, J.G., Aardema, M.J., 2004. Identification of a gene expression profile that discriminates indirect-acting genotoxins from direct-acting genotoxins *Mutat. Res. Genet. Toxicol. Environ. Mutagen.* 549, 5–27.
- Jais, J.P., Haioun, C., Molina, T.J., Rickman, D.S., de Reynies, A, Berger, F, Gisselbrecht, C., Briere, J., Reyes, F., Gaulard, P., Feugier, P., Labouyrie, E., Tilly, H., Bastard, C., Coiffier, B., Salles, G., Leroy, K., 2008. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. *Leukemia* 22, 1917–1924.

Formatted: Spanish (Spain)

Field Code Changed

Formatted: German (Germany)

- Jones, B., Roberts, P.J., Faubion, W.A., Kominami, E., Gores, G.J., 1998. *CSTA* expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. *Am. J. Physiol. Gastrointest. Liver Physiol.* 275, G723–730.
- Kawata, K., Shimazaki, R., Okabe, S., 2009. Comparison of gene expression profiles in HEPG2 cells exposed to arsenic, cadmium, nickel, and three model carcinogens for investigating the mechanisms of metal carcinogenesis. *Environmen. Mol. Mutagen.* 50, 46–59.
- Kepler, D., 2006. Towards novel anti-cancer strategies based on cystatin function. *Cancer Lett.* 235, 159–176.
- Kirkland, D., Kasper, P., Mueller, L., Corvi, R., Speit, G., 2008. Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: A follow-up to an ECVAM workshop. *Mutat. Res. Genet. Toxicol. Environ. Mutagen.* 653, 99–108.
- Konac, E., Ekmekci, A., Barkar, V., Yilmaz, A., Erbas, D., 2005. Effects of diethylstilbestrol in human lymphocytes *in vitro*: A dose and time-dependent study on genotoxic, cytotoxic and apoptotic effects. *Mol. Cel. Biochem.* 276, 45–53.
- Kovacic, P., 2011. Hydroxyurea (therapeutics and mechanism): Metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. *Med. Hypotheses* 76, 24–31.
- Kuopio, T., Kankaanranta, A., Jalava, P., Kronqvist P., Kotkansalo, T., Weber, E., Collan, Y., 1998. Cysteine proteinase inhibitor cystatin A in breast cancer. *Cancer Res.* 58, 432–436.
- Kuzbari, O., Peterson, C.M., Franklin, M.R., Hathaway, L.B., Johnstone, E.B., Hammoud, A.O., Lamb, J.G., 2013. Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: Implications for toxicity testing paradigms. *Reprod. Toxicol.* 37, 24–30.
- Lakin, N., Jackson, S.P., 1999. Regulation of p53 in response to DNA damage. *Oncogene* 18, 7644–7655.
- Li, C., Chen, L., Wang, J., Zhan, L., Tang, P., Zhai, S., Guo, W., Yu, N., Zhao, L., Liu, M., Yang, S., 2011. Expression and clinical significance of cathepsin B and stefin A in laryngeal cancer. *Oncol. Rep.* 26, 869–875.
- Liu, Y., Masson, J.Y., Shah, R., O'Regan, P., West, S.C., 2004. RAD51C is required for holliday junction processing in mammalian cells. *Science* 303, 243–246.
- McElwee, M.K., Song, M.O., Freedman J.H., 2009. Copper activation of NF- κ B signaling in HEPG2 Cells. *J. Mol. Biol.* 393, 1013–1021.
- Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund M., Lichtner, P., Hartmann, L., Schaal, H., Ramser, J., Honisch, E., Kubisch, C. Wichmann H.E., Kast, K., Deissler, H. Engel, C., Mueller-Myhsok, B., Neveling, K., Kiechle, M., Mathew, C., Schindler, D., Schmutzler R.K.,

- Hanenberg, H., 2010. Germline mutations in breast and ovarian cancer pedigrees establish *RAD51C* as a human cancer susceptibility gene. *Nature Genet.* 42, 410–414.
- Meplan, C., Richard, M.J., Hainaut, P., 2000. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators *in vitro* and in intact cells. *Oncogene* 19, 5227–5236.
- Moffitt, K.L., Martin, S.L., Walker, B., 2010. Proteases implicated in apoptosis: old and new. *J. Pharm. Pharmacol.* 62, 563–576.
- Morris, C.A., El-Hiti, G.A., Weeks, I., Woodhead, S., Smith, K., Kille, P., 2012. Utilising chemiluminescent methods for animal-free toxicology tests. *Toxicol. Lett.* 211, S104–S105.
- Morris, C.A., Owen, J.R., Thomas, M.C., El-Hiti, G.A., Harwood, J.L., Kille, P., 2014. Intracellular localization and induction of a dynamic RNA-editing event of macro-algal V-ATPase subunit A (VHA-A) in response to copper. *Plant Cell and Environ.* 37, 189–203.
- Muller, A., Boitier, E., Hu T., Carr, G.J., Le Fevre, A.C., Marchandea, J.P., Flor, M., Jefferson, F., Aardema, M.J., Thybaud, V., 2005. Laboratory variability does not preclude identification of biological functions impacted by hydroxyurea. *Environmen. Mol. Mutagen.* 46, 221–235.
- Muñoz, B. & Albores A., 2011. DNA damage caused by polycyclic aromatic hydrocarbons: mechanisms and markers, in: *Selected Topics in DNA repair.* Clark C. Chen (Eds), p.p. 125-144 InTech, DOI: 10.5772/22527. Available from: <http://www.intechopen.com/books/selected-topics-in-dna-repair/dna-damage-caused-by-polycyclic-aromatic-hydrocarbons-mechanisms-and-markers>
- Narayanan, V.S., Fitch, C.A., Levenson, C.W., 2001. Tumor suppressor protein p53 mRNA and subcellular localization are altered by changes in cellular copper in human Hep G2 cells. *J. Nutr.* 131, 1427–1432.
- Nelson, N.S., Reynolds M. Arnold L.J., 1992. Detection of acridinium esters by chemiluminescence In: *Nonisotopic DNA probe techniques.* Kricka, I. J. (Eds.) Academic, San Diego, C.A., U.S.A., pp. 275–310.
- Nelson, N.C., Hammond, P.W., Matsuda, E., Goud, A.A., Becker, M.M., 1996a. Detection of all single-base mismatches in solution by chemiluminescence. *Nucleic Acids Res.* 24, 4998–5003.
- Nelson, N.C., BenCheikh, A., Matsuda, E., Becker, M.M., 1996b. Simultaneous detection of multiple nucleic acid targets in a homogeneous format. *Biochemistry* 35, 8429–8438.
- Obata H., Sawada, N., Isomura, I., Mori, M., 1996. Abnormal accumulation of copper in LEC rat liver induces expression of p53 and nuclear matrix-bound p21waf/cip1. *Carcinogenesis* 17, 2157–2161.
- Osterburg, A.R., Robinson, C.T., Schwemberger, S., Mokashi, V., Stockelman, M., Babcock, G.F., 2010. Sodium tungstate (Na₂WO₄) exposure increases apoptosis in human peripheral blood lymphocytes. *J. Immunotoxicol.* 7, 174–182.

- Permenter, M.G., Lewis, J.A., Jackson, D.A., 2011. Exposure to nickel, chromium, or cadmium causes distinct changes in the gene expression patterns of a rat liver derived cell line. *PLoS One* 6 (11), e27730. doi: 10.1371/journal.pone.0027730.
- Phatak, V.M., Muller, P.A.J., 2015. Metal toxicity and the p53 protein: an intimate relationship. *Toxicol. Res.* 4, 576–591.
- Powell, E., Piwnica-Worms, D., Piwnica-Worms, H., 2014. Contribution of p53 to metastasis. *Cancer Discov.* 4, 405–414.
- Sakano, K., Oikawa, S., Hasegawa, K., Kawanishi, S., 2001. Hydroxyurea induces site-specific DNA damage *via* formation of hydrogen peroxide and nitric oxide. *Jpn. J. Cancer Res.* 92, 1166–1174.
- Schmittgen, T.D., Livak, H.J., 2008. Analyzing real-time PCR data by the comparative C_T method. *Nat. Protoc.* 3, 1101–1108.
- Song, M.O., Li, J., Freedman, J.H., 2009. Physiological and toxicological transcriptome changes in HEPG2 cells exposed to copper. *Physiol. Genomics* 38, 386–401.
- Sharan, S.K., Kuznetsov, S.G., Sergey, G., 2007. Resolving RAD51C function in late stages of homologous recombination. *Cell Div.* 2, doi: 10.1186/1747-1028-2-15.
- Sinha, A.A., Quast, B.J., Korkowski, J.C., Wilson, M.J., Reddy, P.K., Ewing, S.L., Sloane, B.F., Gleason, D.F., 1999. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score. *Anticancer Res.* 19, 2821–2829.
- Tacar O., Sriamornsak P., Crispin R. Dass C.R., 2012 Doxorubicin: an update on anticancer molecular. action, toxicity and novel drug delivery systems. *Journal of Pharmacy and Pharmacology*, 65, 157–170.
- Takahashi, H., Komatsu, N., Ibe, M., Ishida-Yamamoto, A, Hashimoto, Y., Iizuka, H., 2007. Cystatin A suppresses ultraviolet B-induced apoptosis of keratinocytes. *J. Dermatol. Sci.* 46, 179–187.
- Takahashi, P., Polson, A., Reisman, D., 2011. Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cycle. *Apoptosis* 16, 950–958.
- Tassabehji, N.M., VanLandingham, J.W., Levenson, C.W., 2005. Copper alters the conformation and transcriptional activity of the tumor suppressor protein p53 in human Hep G2 cells. *Exp. Biol. Med.* 230, 699–708.
- Thomas-Jones, E., Thorpe, K., Harrison N., Thomas G., Morris C., Hutchinson T., Woodhead S., Tyler, C., 2003a. Dynamics of estrogen biomarker responses in rainbow trout exposed to 17 beta-estradiol and 17 alpha-ethinylestradiol. *Environ. Toxicol. Chem.* 22, 3001–3008.
- Thomas-Jones, E., Walkley, N., Morris C., Kille, P., Cryer, J., Weeks, I., Woodhead, JS., 2003b. Quantitative measurement of fathead minnow vitellogenin mRNA using hybridization protection assays. *Environ. Toxicol. Chem.* 22, 992–995.

Formatted: German (Germany)

Formatted: Spanish (Spain)

VanLandingham, J.W., Fitch, C., Levenson, C.W., 2002. Zinc inhibits the nuclear translocation of the tumor suppressor protein p53 and protects cultured human neurons from copper-induced neurotoxicity. *NeuroMolecular Med.* 1, 171–182.

Verma, R., Xu, X., Jaiswal, M., Olsen, C., Mears, D., Caretti, G., Galdzicki, Z., 2011. *In vitro* profiling of epigenetic modifications underlying heavy metal toxicity of tungsten-alloy and its components. *Toxicol. Appl. Pharmacol.* 253, 178–187.

Wain, H.A., Bruford, E. A., Lovering, R.C., Lush, M.J., Wright M.W., Povey S., 2002. Guidelines for Human Gene Nomenclature. *Genomics* 79, 464-470

Waisberg, M., Joseph, P., Hale, B., Beyersmann, D., 2003. Molecular and cellular mechanisms of cadmium carcinogenesis. *Toxicology* 192, 95–117.

Formatted: German (Germany)

Wang, C.Y., Wang Y.T., Tzeng, D.W., Yang, J.L., 2009. Lead acetate induces EGFR activation upstream of SFK and PKC alpha linkage to the Ras/Raf-1/ERK signalling. *Toxicol. Appl. Pharmacol.* 235, 244–252.

Wang, Y.T., Tzeng, D.W., Wang, C.Y., Hong, J.Y., Yang, J.L., 2013. APE1/Ref-1 prevents oxidative inactivation of ERK for G(1)-to-S progression following lead acetate exposure. *Toxicology* 305, 120–129.

Westerink, W.M.A., Schoonen, W.G.E.J., 2007a. Cytochrome P450 enzyme levels in HEPG2 cells and cryopreserved primary human hepatocytes and their induction in HEPG2 cells. *Toxicol. Vitro* 21, 1581–1591.

Formatted: German (Germany)

Westerink, W.M.A., Schoonen, W.G.E.J., 2007b. Phase II enzyme levels in HEPG2 cells and cryopreserved primary human hepatocytes and their induction in HEPG2 cells. *Toxicol. Vitro* 21, 1592–1602.

Formatted: German (Germany)

Westerink, W.M.A., Stevenson, J.C.R., Horbach, G.J., Schoonen, W.G.E.J., 2010. The development of *RAD51C*, *Cystatin A*, *p53* and *Nrf2* luciferase-reporter assays in metabolically competent HEPG2 cells for the assessment of mechanism-based genotoxicity and of oxidative stress in the early research phase of drug development. *Mutat. Res. Genet. Toxicol. Environ. Mutagen.* 696, 21–40.

Zhang, L., Xiao, H., Karlan, S., Zhou, H., Gross, J., Elashoff, D., Akin, D., Yan, X., Chia, D., Karlan, B., Wong, D.T., 2010. Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. *PLoS One* 5 (12), e15573 doi: 10.1371/journal.pone.0015573.

Supplementary Figure 1: Changes in global gene expression.

